Daniel P. Rakiec

TL;DR: It is suggested that emergence of F876L may serve as a novel biomarker for prediction of drug sensitivity, predict a "withdrawal" response to MDV3100, and be suitably targeted with other antiandrogens or CDK4/6 inhibitors.

TL;DR: It is suggested that resistant clones are present before treatment, which would make up-front therapeutic combinations that target non-overlapping resistance a preferred approach and ClonTracer barcoding may be a valuable tool for optimizing therapeutic regimens with the goal of curative combination therapies for cancer.

TL;DR: It is shown that CRISPR-based screens have a significantly lower false-negative rate compared with RNAi- based screens, but have specific liabilities particularly in the interrogation of regions of genome amplification, therefore, this study provides critical insights for applying CRISpr-based screening toward the systematic identification of new cancer targets.

TL;DR: It is revealed that NIK is a new therapeutic target for MCL treatment, particularly for lymphomas that are refractory to BCR pathway inhibitors and provide critical insights into patient stratification strategies for NF-κB pathway–targeted agents.

TL;DR: The output of IFN signaling, specifically IFN-stimulated gene (ISG) signatures, in primary tumors from The Cancer Genome Atlas is characterized and it is shown that ISG transcriptional state creates a novel genetic vulnerability.